Ramesh K. Ramanathan, MD, discusses the potential of identifying actionable targets in appendiceal cancers.
The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.
The ability of clinicians to improve treatment outcomes that gemcitabine offers for patients with metastatic pancreatic cancer is expected to move forward now that the FDA has approved a new indication for nab-paclitaxel (Abraxane) as part of a combination regimen, according to researchers.
The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.
The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.
Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.
Ramesh K. Ramanathan, MD, from the Virginia G. Piper Cancer Center, discusses the phase III MPACT study that examined gemcitabine plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas.